Anamorelin Study for Advanced Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

December 31, 2024

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

Anamorelin Hydrochloride

Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects.

DRUG

Placebo

Anamorelin placebo

Trial Locations (1)

01805

RECRUITING

Lahey Hospital & Medical Center, Burlington

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Helsinn Healthcare SA

INDUSTRY

collaborator

Quartesian LLC

UNKNOWN

lead

Lahey Clinic

OTHER